COMPARISON
Carfilzomib vs Ciclosporin
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Carfilzomib is authorised or registered in 10 and Ciclosporin in 9 of the 10 registers read. Carfilzomib: highest phase Phase 3 (14 phase 3 trials, 0 with posted results). Ciclosporin: highest phase Phase 4 (after approval). 1 registered trial includes both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Carfilzomib | Ciclosporin | |
|---|---|---|
| Registered trials differs | 308 clinicaltrials.gov · 2026-10-03 | 1328 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: KYPROLIS openfda · 2026-10-03T17:23:44.062Z | FDA label, application not recorded: VEVYE openfda · 2026-08-31T07:37:14Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2015-11-19 ema · 2026-10-03 | 2015-03-19 ema · 2026-10-03 |
| ATC code differs | L01XX45 ema · 2026-10-03 | S01XA18 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Carfilzomib | placebo | Ciclosporin | placebo |
|---|---|---|---|---|
| Punctate Keratitis | - | - | 5.8% | 4.5% |
Trial register Carfilzomib: 0 placebo-controlled trials; Ciclosporin: 7. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Carfilzomib side effects · Ciclosporin side effects
LEGAL STATUS
Approval in each country read
| Country | Carfilzomib | Ciclosporin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA label, application not recorded | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
1 registered trial includes both
| NCT04813653 | Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myelom COMPLETED · updated 2025-07-24 |
|---|
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.